Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis

BACKGROUND: Mutations in the RAS‐MAPK pathway, such as KRAS, NRAS, and BRAF, are known as high‐risk factors associated with poor prognosis in patients with various cancers, but studies in myeloma have yielded mixed results. METHODS: We describe the clinicopathologic, cytogenetic, molecular features,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Nianyi, Lin, Pei, Zuo, Zhuang, You, M. James, Shuai, Wen, Orlowski, Robert, Manasanch, Elisabet E., Li, Shaoying, Xu, Jie, Garces, Sofia, Jelloul, Fatima Zahra, Tang, Zhenya, Wang, Wei, Medeiros, L. Jeffrey, Yin, C. Cameron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358222/
https://www.ncbi.nlm.nih.gov/pubmed/37212518
http://dx.doi.org/10.1002/cam4.6103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358222/
https://www.ncbi.nlm.nih.gov/pubmed/37212518
http://dx.doi.org/10.1002/cam4.6103

Ejemplares similares